A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
{{output}}
The development of resistance to tyrosine kinase inhibitors (TKIs) in metastatic non-small cell lung cancer (NSCLC) with oncogenic driver mutations highlights the challenge in improving the survival of these patients. The standard of care for ALK-rearranged ad... ...
